Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic fibroblasts
- Development stage
- Phase 2
- Lead developer
- Hmg Biologics
- Modality
- Cell Therapies
- Administration
- Topical
01
Overview
Allogeneic fibroblasts is a cell therapy product under development by HMG Biologics for the treatment of chronic refractory wounds, such as diabetic foot ulcers or venous leg ulcers. The therapy utilizes fibroblasts sourced from healthy donors, which are processed and applied to the site of injury. These allogeneic cells function by secreting a variety of essential proteins, including collagen, fibronectin, and growth factors (such as VEGF and PDGF), which facilitate the reconstruction of the extracellular matrix, promote angiogenesis, and stimulate the patient's own cells to accelerate the healing process. The program is currently in Phase 1/2 clinical trials.
- Other names
- allogeneic fibroblast therapy
Beyond the preview
Go deeper on allogeneic fibroblasts.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic fibroblasts.